Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › FL › Tampa › NPI 1821409756
Lab

Medical Dna Labs, LLC

Medical Dna Labs, LLC was paid $107K by Medicaid between Dec 2019 and May 2023, across 28 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 34% of everything it billed.

33Billing provider infoMEDICAL DNA LABS, LLC
TAMPA, FL 33609
33aNPI1821409756assigned 05/14/2014
28Total paid$107K
24GClaims13,999
24DCodes billed28
24AFirst – last monthDec 2019 – May 2023
Compared with peers

Next to other Clinical Medical Laboratory providers in Florida

Rank by total paid#100 of 225
Median peer was paid$74K
This provider vs. median1.5×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official GARI, TRACIE controls 12+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$5.0K$10K$15K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
2019520$1K
20206,324$46K
20214,538$32K
20221,499$27K
20231,118$1K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0004 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r 34% 1,242 1,005 $36K
81225 23% 522 447 $25K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 12% 1,448 1,096 $13K
G2023 Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source 11% 729 571 $12K
81355 9.5% 505 443 $10K
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 2.3% 776 600 $2K
81479 Unlisted molecular pathology procedure 1.6% 1,996 444 $2K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 1.1% 14 12 $1K
80346 <1% 229 76 $1K
81401 <1% 1,319 450 $1K
82955 <1% 510 440 $333.12
80348 <1% 88 63 $261.11
16 more codes
80356 <1% 87 $261.06
80362 <1% 87 $261.06
80373 <1% 88 $261.06
80365 <1% 116 $245.75
80361 <1% 145 $245.75
83992 <1% 87 $245.66
80358 <1% 86 $238.40
80359 <1% 145 $238.00
80353 <1% 115 $238.00
80324 <1% 117 $238.00
81227 <1% 527 $51.96
81226 <1% 525 $51.96
81291 <1% 526 $47.42
81240 <1% 521 $22.68
81400 <1% 929 $11.34
81241 <1% 520 $11.34

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialGARI, TRACIE (CHIEF ADMINISTRATIVE OFFICER)
Same official

Other billing entities under GARI, TRACIE

Full network →

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.